Navigating challenges in ADC development

Antibody-Drug Conjugates (ADCs) are notoriously tricky to develop, due to their delicate nature and the barriers facing their delivery. Andreas Dreps, Senior Vice President, Drug Development Services at ICON Biotech, highlights key obstacles in the development of ADCs and why the future remains bright for this targeted therapy, as he explores:

Tumor heterogeneity, resistance and off-target effects
Delicate nature of ADCs
Need for highly refined manufacturing protocols
Advances in linker chemistry, design and manufacturing of mABs
ADCs as a neoadjuvant therapy in breast cancer

Read the Article

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By completing this form you agree ICON may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy. By clicking submit, you consent to allow Citeline to store and process the information submitted to provide you the content requested. They are subject to their Terms and Conditions.

Navigating challenges in ADC development

Read the Article

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space